ReviewThe breast journal2026
Axillary Recurrence After a Negative Sentinel Lymph Node Biopsy (SLNB) for Initial Positive Node Breast Cancer Postneoadjuvant Therapy: Insights From a Systematic Review and Meta-Analysis.
Review in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the use of sentinel lymph node biopsy (SLNB) to stage the axilla in clinically node-negative breast cancer patients' postneoadjuvant therapy, the incidence and clinical significance of axillary recurrence (AR) after a negative SLNB remain under-explored in the literature. Understanding these factors is essential to improving patient outcomes and guiding future treatment strategies. Methods: We conducted a systematic review and meta-analysis using PubMed, Scopus, ScienceDirect, and Google Scholar. A random effects model was used to calculate pooled incidence of AR, while heterogeneity was assessed using the I Results: A total of 37 studies were included in the qualitative synthesis and meta-analysis. The pooled analysis of these studies highlights a remarkably low incidence of AR, with an overall proportion of 1% (95% CI: [0.0%, 1.0%]) under a random-effects model and no significant heterogeneity ( Conclusion: The meta-analysis demonstrated a remarkably low incidence of AR after a negative SLNB in initially node-positive breast cancer patients postneoadjuvant therapy. These findings suggest that such recurrences are rare, supporting the reliability of SLNB in accurately staging the axilla. This highlights its importance in clinical decision-making for treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.